Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma. (December 2020)

• Record Type: Journal Article
• Authors: Steinhardt, Maximilian Johannes; Zhou, Xiang; Krummenast, Franziska; Meckel, Katharina; Nickel, Katharina; Böckle, David; Messerschmidt, Janin; Knorz, Sebastian; Dierks, Alexander; Heidemeier, Anke; Lapa, Constantin; Einsele, Hermann; Rasche, Leo; Kortüm, Klaus Martin
• Is Part Of: International journal of immunopathology and pharmacology. Volume 34(2020)
• Publication Date: 2020-12
• Subjects: CD38 -- MOR202 -- daratumumab -- multiple myeloma -- refractory -- relapse; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/2058738420980258
• Languages: English
• ISSNs: 0394-6320

Abstract

We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab ("Pom-PAD-Dara"), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.